Lilly's new generation weight loss drug can significantly reduce weight, with equally noticeable side effects.

Several patients participating in the Phase III trial of the new weight-loss drug Retatrutide from Lilly (LLY.US) have reported significant weight loss, but also noticeable side effects. Some trial participants who preferred not to disclose their names reported experiencing side effects such as nausea and kidney stones. Another participant mentioned that they had lost a lot of weight and were advised by their doctor to eat high-calorie foods. However, since the trial was randomized and placebo-controlled, participants did not know whether they were receiving Retatrutide or a placebo. It is reported that the weight loss of three participants was as follows: 22% in 9 months, 30% in 8 months, and 31% in 8-9 months. In addition to weight loss, patients also noticed some positive effects during the trial, such as improvements in knee pain, high cholesterol, and fatty liver disease. Retatrutide, a GLP-1/GIP/GCG triple-target agonist being developed by Lilly, is considered the next generation product to replace liraglutide. Trial data shows that compared to liraglutide (the active ingredient in Lilly's weight-loss drug Zepbound), Retatrutide's Phase II data is even more impressive - in the Phase II clinical trial, the average weight loss rate for Retatrutide was 17.5% at 24 weeks and 24.2% at 48 weeks from baseline (initial weight).